Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
The Institute for New Era Strategy (INES) is calling for a renewed debate on introducing a macroeconomic indexing mechanism for drug spending, arguing that discussions should begin now as policymakers consider broader healthcare spending reforms. The push comes as the…
To read the full story
Related Article
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
ORGANIZATION
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
- Labor Group Urges MHLW to Support Pharma Talent Development
June 3, 2026
- Labor Group Urges Govt to View Pharma as Investment, Not Cost
June 1, 2026
- Global Pharma CEOs Urge Japan PM to Boost Support for Innovative Drugs
May 29, 2026
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…